With the decreasing of birth rate and population in our country, population problem has become a long-term and strategic problem. In addition to the decrease in the number of women of childbearing age and the impact of unmarried women, the increase in the incidence of reproductive disorders and the delay of marriage and childbearing are also important factors leading to the continuous decline of the birth population in China. Among them, ovarian aging is a key factor causing female fertility difficulties. Therefore, establishing an effective prevention and treatment strategy for ovarian aging is of great significance for improving female reproductive health and serving the national population strategy. Recently, several supplements have been found to promote folliculogenesis and improve oocyte quality. However, to date, there is no approved therapeutic agent for the treatment of ovarian aging. Therefore, it is urgent to develop effective strategies for the prevention and treatment of ovarian aging.
Salidroside is the main active component of Chinese medicine Rhodiola, and its content is highest in the root of rhodiola, which is also the main medicinal part. The main efficacy of salidroside in traditional Chinese medicine is to benefit qi, promote blood circulation, unblock pulse and relieve asthma. At the same time, in basic research, more and more experiments have shown that salidroside has a variety of pharmacological properties, including anti-hypoxia, anti-fatigue and anti-aging effects, anti-cancer, anti-inflammatory, anti-oxidation, antiviral and so on. These pharmacological effects suggest that salidroside may be an effective drug for the prevention and treatment of atherosclerosis, Parkinson's disease, Alzheimer's disease, pneumonia and other diseases. In terms of aging, it has been confirmed that salidroside supplementation can prolong the life span of pseudogill oryzias zhan and rescue premature aging of human skin fibroblasts, etc., which further confirms.
The aim of this study is to investigate the efficacy of salidroside as an adjuvant drug in improving the pregnancy outcomes of fresh embryo transfer in high childbearing age patients with poor ovarian response by comparing the pregnancy outcomes of fresh embryo transfer between salidroside group and blank control group. This pragmatic clinical study is expected to improve pregnancy outcomes of fresh embryo transfer cycles in women of advanced childbearing age with poor ovarian response.
Age ≥35 and < 40 years old
For the first or second cycle of IVF, ICSI or IVF with donor sperm
According to the 2016 Poseton criteria for poor prognosis: the number of oocytes obtained in the previous routine ovulation induction protocol was 1-9, or AFC < 5 or AMH < 1.2ng/ml (measured within the past half year) in both ovaries.
Patients with coagulation disorders
Patients with previous abnormal uterine bleeding
Combined with hydrosalpinx confirmed by B-ultrasound and HSG
Uterine malformation (unicornuate uterus, septate uterus) or history of intrauterine adhesions
Parallel
Salidroside
DrugIn the salidroside group, oral administration of rhodiola capsules (Xizang Gaoyuan 'an Biotechnology Development Co., LTD.) was started on the day of entering the COS cycle, once a day, 2 pills at a time, and the drug was stopped on the trigger day.
Ongoing pregnancy rate
The number of continuous pregnancy cycles divided by the number of frozen embryo transfer cycles
Clinical pregnancy rate
The number of clinical pregnancy cycles divided by the number of transplantation cycles
Biochemical pregnancy rate
The number of biochemical pregnancy cycles divided by the number of transplantation cycles
Live birth rate
The number of live birth cycles divided by the number of transplantation cycles
Embryo implantation rate
The ratio of the number of gestational sacs observed by ultrasound to the number of transplanted embryos
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
